San Diego, CA (PRWEB) October 08, 2014
Histogen Oncology, a company developing innovative cancer therapies based on Histogen’s regenerative medicine technology, today announced that the United States Patent & Trademark Office has issued patent 12/363,479 entitled “Extracellular matrix compositions for the treatment of cancer” to Histogen.
The patent, which is the fifth U.S. patent issued to Histogen, covers the soluble and insoluble compositions of proteins and cofactors that are secreted by multipotent stem cells through Histogen’s technology process for use in the treatment of cancer. The patent claims to support the use of the compositions alone or as a delivery system for traditional chemotherapeutic agents.
Through the recent formation and funding of the Histogen Oncology joint venture, research and development of the unique, naturally secreted compositions is progressing toward a Phase I clinical trial for end stage pancreatic cancer.
“We are pleased about the timely issuance of our U.S. patent for the treatment of cancer,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “Our collaborations with top institutions continue to produce mounting evidence supporting the unique mechanism of action of our secreted material in preventing metastasis and reducing tumor load while having no toxic affect on normal cells.”
Histogen’s composition has shown effectiveness in inhibiting over 21 human cancer cell lines both in vitro as well as in animal models. The mechanism of action of the secreted material is through the induction of apoptosis (controlled cell death) primarily in malignant cells, so there is little to no toxicity to normal cells. Histogen Oncology is studying the efficacy of a small molecular weight fraction of the cell secreted composition as a stand alone treatment as well as in combination therapy to evaluate whether effectiveness can be demonstrated with less toxic drug doses.
About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.